ProPhase Labs, Inc.

Distress signal

Moderate confidence (50%)

Updated Oct 19, 2026, 12:03 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: ProPhase Labs, Inc. was delisted from its exchange (Jan 23, 2026)

Every material event, newest first. History is never overwritten.

ProPhase Labs, Inc. was delisted from its exchange
Jan 23, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0000868278 ProPhase Labs, Inc. 000-21617 621 Shady Retreat Road Kells Building Doylestown PA PENNSYLVANIA 18901 215 345-0919 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-01-23”
ProPhase Labs, Inc. received a delisting notice from its exchange
Dec 29, 2025
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 29, 2025, ProPhase Labs, Inc. (the Company ) received a letter from the staff of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period, to regain compliance with the minimum bid price requirement, which exp…”

Every material source used to build this profile.

SEC Company Submissions (TIER 1 · UNVERIFIED)
ProPhase Labs, Inc. — Pharmaceutical Preparations (SIC 2834) — NEW YORK, NY
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0000868278 ProPhase Labs, Inc. 000-21617 621 Shady Retreat Road Kells Building Doylestown PA PENNSYLVANIA 18901 215 345-0919 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-01-23
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 29, 2025, ProPhase Labs, Inc. (the Company ) received a letter from the staff of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period, to regain compliance with the minimum bid price requirement, which exp…
View source record

Every derived status, with the rule that produced it.

DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:29 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:59 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:54 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.